Background: Recombinant hypoallergenic allergen derivatives have been used in
| INTRODUCTION
Allergen-specific immunotherapy (AIT) is an effective, disease-modifying, and long-lasting treatment for IgE-associated allergy. [1] [2] [3] AIT has been conducted originally by vaccination with natural allergen extracts containing allergens in their native structure. 4 To increase the safety of AIT, denatured allergen extracts termed allergoids have been introduced in which the native allergens have been chemically modified to lose their structure and conformational IgE epitopes. 5, 6 Despite the loss of the native structure, allergoids seem to induce allergen-specific blocking IgG antibodies [7] [8] [9] [10] which are thought to be responsible for clinical efficacy of AIT besides alterations of cellular and cytokine responses. 3 With the availability of recombinant allergens and DNA as well as peptide-based technologies, recombinant and synthetic allergen derivatives have been engineered for several important allergens which resemble many features of allergoids, in particular reduced IgE reactivity and reduced allergenic activity. 11, 12 Several clinical studies performed with such recombinant allergen derivatives and synthetic allergen fragments lacking the folding of natural allergens indicate that the treatment is clinically effective and is associated with the induction of allergen-specific IgG antibodies which compete with allergic patients 0 IgE for binding to the natural, native allergens. [13] [14] [15] [16] Although IgG antibodies induced with recombinant hypoallergenic allergen derivatives and allergen-derived peptides are raised against unfolded allergen derivatives, they seem to induce IgG antibodies in patients which recognize also the folded native allergens. 
| METHODS

| Materials
Materials, sera, and reagents are described in the Data S1. Therapy. The subject gave written informed consent. The subjects'
|
IgG to Bet v 1 (2 lg/mL), Bet v 1 fragments (1 lg/mL), or peptides (1 lg/mL) was determined by ELISA. After Bet v 1, fragments or peptides were coated for 5 hours at room temperature to ELISA plates (Nunc Maxi-Sorp, Roskilde, Denmark), plates were blocked with PBST containing 2% BSA (wt/vol) overnight at 4°C. Serum samples diluted 1:100 were incubated overnight at 4°C, and specific IgG levels were detected with a rabbit anti-human IgG antiserum (Jackson Immuno) followed by a horseradish peroxidaselabeled donkey anti-rabbit antiserum (GE Healthcare, Little Chalfont, UK) diluted 1:10 000 and 1:2000, respectively, in PBST containing 0.5% BSA (wt/vol). Color reaction was read at 405 nm, and results are means of duplicates.
Peripheral blood mononuclear cells were isolated 10 days after the third injection when allergen-specific IgG had developed ( Figure 1 ) by Ficoll Paque (GE Healthcare) density gradient centrifugation for the construction of the combinatorial library (see Data S1).
| Isolation of a Bet v 1-specific ScFv
After library transformation in E. coli TG1, phages were rescued with M13KO7 helper phage and the phage library was subjected to four rounds of solid phase panning. For this purpose, ELISA wells (Nunc, Roskilde, Denmark) were coated with Bet v 1 (1 lg/ well in 1xPBS), blocked, and incubated with the phage library. After the 3rd and 4th round of panning, an aliquot of transduced TG1 was plated to SOBAG plates for screening purposes (Amersham Biosciences). To this aim, single-phage clones were rescued, incubated with ELISA plate-bound Bet v 1 (10 lg/mL), and detected with an anti-M13 antiserum (GE Healthcare) as described for the panning.
Bet v 1-specific phage clones were sequenced (Eurofins Genomics).
Obtained sequences were aligned with human germline gene sequences from the IMGT database using V-Quest software. 19 Ancestor germline genes were determined, and the positions of mutations were identified. Phagemid DNAs were transformed into the nonsuppressor E. coli strain HB2151 for expression of soluble ScFvs carrying a peptide E tag at the C-terminus. 20 Additionally,
ScFvs carrying a C-terminal His tag were constructed as described. 21 Soluble Bet v 1-specific ScFvs were purified by affinity chromatography. 22 The biochemical and structural characterization of H3-1 is described in the Data S1. 
|
| Multiple sequence alignment
The amino acid sequences of Bet v 1 (Swissprot accession number: were not included in the inhibition calculation. Percentage reductions of patients' IgE binding after pre-incubation with H3-1 compared to the control ScFv were calculated as follows: 100-(OD after pre-incubation with H3-1 * 100/OD after pre-incubation with control ScFv).
All determinations were performed in duplicates, and median values were calculated.
Statistically significant differences of IgE binding after pre-incubation with H3-1 versus pre-incubation with control ScFv were determined by Mann-Whitney test using Prism 5.04 (GraphPad Software, La Jolla, CA, USA).
| Effect of H3-1 on Bet v 1-induced basophil activation
The effect of H3-1 on Bet v 1-induced basophil activation was measured by detecting CD203c upregulation as described 26 (Data S1). that each clone represented an independent antibody (Data S1, Table S1 ), confirming the nonredundant nature of the library. The VH family distribution was dominated by members of the largest gene subgroup, the VH3 family, followed by VH1 > VH6 > VH2/ VH4 > VH5 (Data S1, Table S1 ). The VK family distribution was dominated by VK3 followed by VK1/4 > VK7 > VK2/5/6 (Table S1 ). Figure 2A ) and differed only in one nucleotide located in CDR2 and two in CDR3 resulting in two amino acid exchanges (Data S1, Table S2 ). The D gene of the H3-1_HV was derived from its germline progenitor IGHD2-15*01. The J gene showed 100% sequence identity to the germline IGHJ6*02 (Figure 2A) .
| RESULTS
| Construction of a combinatorial phagedisplayed ScFv library from a subject immunized with rBet v 1 fragments and isolation of a Bet v 1-specific ScFv
The H3-1 light chain (H3-1_KV) had 98.32% nucleotide sequence identity with its closest related V germline progenitor gene IGKV4-1*01 ( Figure 2B ) and differed in five nucleotides (FR1:
2, CDR1: 1, FR2: 1, CDR3: 1) ( Figure 2B , Table S2 ), leading to three amino acid changes (located in FR1, FR2, CDR3) ( Table S2 ).
The J gene of the light chain seemed to originate from IGKJ1*01
( Figure 2B ). T 
|
A B L E 1 Inhibition of allergic patients 0 IgE binding to Bet v 1, Aln g 1, Cor a 1, and Mal d 1 after pre-incubation with H3-1 compared to a control ScFv
| DISCUSSION
Our study is the first to report the molecular characterization of an allergen-specific IgG antibody induced by immunization with recombinant hypoallergenic allergen derivatives in a nonallergic subject. An 
